Clinical Trials
49 trialsEVEREST-2
A2 Biotherapeutics Inc.
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Verismo Therapeutics
SW-682 in Advanced Solid Tumors
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
A Study of Sacituzumab Govitecan in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
National Institutes of Health Clinical Center (CC)
OMIM
Azienda USL Reggio Emilia - IRCCS
BASECAMP-1
A2 Biotherapeutics Inc.
eVOLVE-Meso
AstraZeneca
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
RIOT 4B
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
DUAL-MESO-NK
Beijing Biotech
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
HIT-Meso
University College, London
Bi-MAPS
Intergroupe Francophone de Cancerologie Thoracique
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
InSilico Medicine Hong Kong Limited
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
University of Chicago
IT-TCP POS
Azienda Ospedaliero-Universitaria di Parma
(RIOT 4A)
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Abramson Cancer Center at Penn Medicine
IMPALA
University Hospital, Lille
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Imaging-Meso
Istituto Oncologico Veneto IRCCS
TIGER Meso
NovoCure Ltd.
NECIM
University Hospital, Antwerp
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
ABILITY-1
Medicenna Therapeutics, Inc.
FAPI-PM
Aalborg University Hospital
APG-2449 in Patients With Advanced Solid Tumors
Ascentage Pharma Group Inc.
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
PENINSULA
Hyogo Medical University
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
FLAT
National and Kapodistrian University of Athens
ENSURE
Erasmus Medical Center
Hemithoracic Arc Radiotherapy Post Pleural Decortication
Cairo University
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
University College, London
MAGNETS
Fondazione IRCCS Policlinico San Matteo di Pavia
AtezoMeso
Gruppo Oncologico Italiano di Ricerca Clinica
A Study of MT027 in Patients with Pleural Malignant Tumors
Suzhou Maximum Bio-tech Co., Ltd.
MESORTIBO
Centro di Riferimento Oncologico - Aviano
FAPBI
Ankara University
Immuno-MESODEC
University Hospital, Antwerp
FLT-MM
Ankara University
Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
Sun Yat-sen University
Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma
Tianjin Medical University Second Hospital